TOP TEN perturbations for 39846_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39846_at
Selected probe(set): 203657_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39846_at (203657_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):3.0409336Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
Hep-G2 / HepaRG
Relative Expression (log2-ratio):-2.7340775Number of Samples:9 / 12
Experimental | Hep-G2 |
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: | |
Control | HepaRG |
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
hepatocyte (ESC) / HepaRG
Relative Expression (log2-ratio):-2.5506668Number of Samples:8 / 12
Experimental | hepatocyte (ESC) |
Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
Control | HepaRG |
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)
Relative Expression (log2-ratio):2.1798992Number of Samples:2 / 5
Experimental | colorectal cancer study 43 (metastase; brain) |
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
Control | colorectal cancer study 43 (metastase; lung) |
Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Relative Expression (log2-ratio):2.1775436Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):2.1429625Number of Samples:6 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.125183Number of Samples:2 / 13
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.1120749Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)
Relative Expression (log2-ratio):2.10956Number of Samples:2 / 25
Experimental | colorectal cancer study 43 (metastase; brain) |
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
Control | colorectal cancer study 43 (metastase; liver) |
Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma. |
GDC-0941 study 1 (3.606 uM) / vehicle (DMSO) treated A2058 cell samples
Relative Expression (log2-ratio):2.1049776Number of Samples:4 / 4
Experimental | GDC-0941 study 1 (3.606 uM) |
A2058 cells treated with 3.606 uM GDC-0941 for 24hours. The concentration corresponding to the IC90 of BKM120. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. GDC-0941 is a potent inhibitor of PI3Kα/δ, alternative names: [pictilisib] ATC code:--- | |
Control | vehicle (DMSO) treated A2058 cell samples |
A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. |